Cardioprotective role of Atorvastatin in hyperhomocysteinemic rat hearts

Asian Journal of Pharmaceutical and Clinical Research

Volumn 5, Issue SUPPL 2, 2012, Pages 120-123

  Rohilla, Ankur ^a   Khan, M U ^b   Khanam, Razia ^c  

^a NIMS UNIVERSITY   (India)

^b Sri Sai College of Pharmacy   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

Atorvastatin; Hyperhomocysteinemia; Oxidative stress

Indexed keywords

ATORVASTATIN; CREATINE KINASE MB; GLUTATHIONE; LACTATE DEHYDROGENASE; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME RELEASE; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART PROTECTION; HYPERHOMOCYSTEINEMIA; ISOLATED HEART; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; STAINING;

EID: 84862731123     PISSN: 09742441     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Lv L, Jiang SS, Xu J, Gong JB, Cheng Y. Protective Effect of Ligustrazine Against Myocardial Ischaemia Reperfusion in Rats: Role Of Endothelial Nitric Oxide Synthase. Clin Exp Pharmacol Physiol 2012; 39: 20-7.
2. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning and postconditioning. Pharmacol Rev 2007; 59: 418-58.
3. Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol 2010; 106: 360-8.
4. Rohilla A, Rohilla S, Kushnoor A. Myocardial postconditioning: Next step to cardioprotection. Arch Pharm Res 2011; 34: 1409-15.
5. Loscalzo J. Homocysteine trials-Clear outcomes for complex reasons. N Engl J Med 2006; 354: 1629-32.
6. Ciaccio M, Bellia C. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr Clin Pharmacol 2010; 5: 30-6.
7. Herrmann M, Kindermann I, Muller S. Relationship of plasma homocysteine with the severity of chronic heart failure. Clin Chem 2005; 51: 1512-5.
8. Barabasi AL. Network medicine-From obesity to the "diseasome". N Engl J Med 2007; 357: 404-7.
9. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 2005; 289: H2649-56.
10. Austin R, Lentz S, Werstuck G. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004; 11: S56-64.
11. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis". BMJ 2003; 326: 1423.
12. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial". Lancet 2003; 361: 1149-58.
13. Rohilla A, Rohilla S, Singh G, Kumar A, Khan M.U. Atorvastatin Pleiotropism: Role in Cardioprotection. Int J Pharm Biol Arch 2011; 2: 813-8.
14. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003; 41: 508-15.
15. Efthymiou CA, Yellon DM. Atorvastatin and Myocardial Reperfusion Injury New Pleiotropic Effect Implicating Multiple Prosurvival Signaling. J Cardiovasc Pharmacol 2005; 45: 247-52.
16. Ozacmak VH, Sayan H, Igdem AA, Cetin A, Ozacmak ID. Attenuation of contractile dysfunction by atorvastatin after intestinal ischemia reperfusion injury in rats. Eur J Pharmacol 2007; 562: 138-47.
17. Bolayirli IM, Aslan M, Balci H, Altug T, Hacibekiroglu M, Seven A. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci 2007; 81: 121-7.
18. Langendorff O. Untersuchungen am uberlebenden Saugethierherzen. Archiv fur die gesammte Physiologie des Menschen und der Thiere Bonn 1895, 61: 291-332.
19. Parikh V, Singh M. Possible role of adrenergic component and cardiac mast cell degranulation in preconditioning-induced cardioprotection. Pharmacol Res 1999; 40: 129-37.
20. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-8.
21. Wang HD, Pagano PJ, Du Y, Cayatte AJ, Quinn MT, Brecher P, et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 1998; 82: 810-8.
22. Beutler, E., Duron, O., Kefly, B.M. Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 61: 882-8.
23. Heydari B, Jerosch-Herold M, Kwong RY. Assessment of myocardial ischemia with cardiovascular magnetic resonance. Prog Cardiovasc Dis 2011; 54: 191-203.
24. Kaur H, Parikh V, Sharma A, Singh, M. Effect of amiloride a Na+/H+ exchange inhibitor on cardioprotective effect of ischaemic preconditioning: Possible involvement of resident cardiac mast cells. Pharmacol Res 1997; 36: 95-102.
25. Sharma A, Singh M. Possible mechanism of cardioprotective effect of ischaemic preconditioning in isolated rat heart. Pharmacol Res 2000; 41: 635-40.
26. Ungvari Z, Csiszar A, Edwards JG. Increased superoxide production in coronary arteries in hyperhomocysteinemia: Role of tumor necrosis factor-α, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003; 23: 418-24.
27. Devi S, Kennedy RH, Joseph L, Shekhawat NS, Melchert RB, Joseph J. Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. Cardiovasc Pathol 2006; 15: 75-82.
28. Ozer M, Parlakpinar H, Cigremis Y, Ucar M, Vardi N, Acet A. Ischemia-reperfusion leads to depletion of glutathione content and augmentation of malondialdehyde production in the rat heart from overproduction of oxidants: Can caffeic acid phenethyl ester (CAPE) protect the heart? Mol Cell Biochem 2005; 273: 169-75.
29. Balakumar P, Rohilla A, Singh G, Singh K, Singh M. Modulation of cardioprotective effect of ischemic pre-and postconditioning in the hyperhomocysteinemic rat heart. Methods Find Exp Clin Pharmacol 2009; 31: 71-9.
30. Balakumar P, Singh AP, Ganti GS, Singh M. Hyperhomocysteinemia and cardiovascular disorders: Is there a correlation?. Trends Med Res 2007, 2: 160-6.
31. Shah DI, Singh M. Possible role of Akt to improve vascular endothelial dysfunction in diabetic and hyperhomocysteinemic rats. Mol Cell Biochem 2007; 295: 65-74.
32. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
33. Laufs U, Bohm M. Cardiac effects of statins-advancements and open questions. Cardiovasc Res 2005; 66: 427-9.
34. Rohilla A, Khan MU, Khanam R. Atorvastatin Ameliorates Ischemia Reperfusion Injury in Rat Heart. Int J Pharm Biol Arch 2011; 2: 1431-7.
35. Bhandari U, Pathan RA, Kumar V, Khanna N. Ameliorative role of atorvastatin on methionine-induced hyperhomocysteinemia and hematological changes in albino rats. Indian J Exp Biol 2011; 49: 132-9.
36. Ozacmak VH, Sayan H, Igdem AA, Cetin A, Ozacmak ID. Attenuation of contractile dysfunction by atorvastatin after intestinal ischemia reperfusion injury in rats. Eur J Pharmacol 2007; 562: 138-47.
37. Bolayirli IM, Aslan M, Balci H, Altug T, Hacibekiroglu M, Seven A. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci 2007; 81: 121-7.
38. Castro PF, Miranda R, Verdejo HE, Greig D, Gabrielli LA, Alcaino H, et al. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. J Heart Lung Transplant 2008; 27: 435-41.